|
Aug 1
|
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Down Over 4% for Week
|
|
Jul 28
|
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
|
|
Jul 25
|
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Gain 1.6% for Week
|
|
Jul 25
|
Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
|
|
Jul 23
|
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
|
|
Jul 15
|
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading
|
|
Jul 11
|
European Equities Traded in the US as American Depositary Receipts Drop Sharply in Friday Trading
|
|
Jul 11
|
Evaxion finalizes agreement with EIB to convert debt into equity
|
|
Jul 8
|
European Equities Traded in the US as American Depositary Receipts Advance in Tuesday Trading
|
|
Jul 1
|
European Equities Traded in the US as American Depositary Receipts Edge Higher in Tuesday Trading
|
|
Jul 1
|
Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio
|
|
Jun 27
|
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Up 2.5% for Week
|
|
Jun 17
|
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
|
|
May 28
|
Evaxion AS (EVAX) Q1 2025 Earnings Call Highlights: Strong Cash Position and Promising Vaccine ...
|
|
May 27
|
Evaxion announces business update and first quarter 2025 financial results
|
|
May 27
|
EVAX Previews Exciting Year Ahead
|
|
May 23
|
Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025
|
|
May 22
|
Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01
|
|
Apr 10
|
Evaxion to present at World Vaccine Congress
|
|
Jan 16
|
Evaxion concludes subject dosing in Phase II trial of melanoma vaccine
|